Review of Biologics in Children With Rheumatic Diseases

Shabina Habibi; Athimalaipet V Ramanan

Disclosures

Int J Clin Rheumatol. 2012;7(1):81-93. 

In This Article

Anti-TNF-α Agents

TNF-α has been found to play an important role in the pathogenesis of a variety of inflammatory diseases, including JIA.[5–7] TNF-α-blocking agents bind to and antagonize the effects of TNF-α, acting on both the free molecule in serum and the cell surface-bound molecule. Etanercept, adalimumab and infliximab are the three TNF-α agents used in the therapy of JIA, especially the polyarticular subtype, and juvenile psoriatic arthritis, with polyarticular involvement. Etanercept is a soluble TNF receptor fusion protein, consisting of the extracellular domain of the TNF-α receptor combined with the Fc portion of human immunoglobulin. It binds to soluble TNF-α and thus decreases downstream TNF-α receptor-mediated signaling. Infliximab is a chimeric human–mouse monoclonal antibody directed against TNF-α, whereas adalimumab is a fully humanized monoclonal antibody against TNF-α. Both infliximab and adalimumab bind to both the soluble and membrane-bound TNF-α, neutralizing its effect. These different mechanisms of action between the soluble receptor fusion protein and monoclonal antibodies have implications in choice of and side effects associated with biologics.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....